Pharmacogenetics of psoriasis:<i>HLA-Cw6</i>but not<i>LCE3B/3C</i>deletion nor<i>TNFAIP3</i>polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab

Abstract excerpt

BACKGROUND: Our understanding of the genetic basis of predisposition to psoriasis is increasing exponentially due to the progress of genetic studies. However, so far little is known about genetic predisposition in relation to the response to psoriasis treatments. Recent data identified genetic predictors for the clinical outcome of conventional treatments such as methotrexate, acitretin and vitamin D derivatives,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Psoriasis: Treatment and Pathogenesis
• Share to Spondyloarthritis Studies and Treatments
• Share to Vitamin D Research Studies